Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-Year follow-up data

Annals of Oncology

Volumn 24, Issue 2, 2013, Pages 350-355

  Lintermans, A ^a   Laenen, A ^a   Van calster, B ^a   Van Hoydonck, M ^a   Pans, S ^b   Verhaeghe, J ^a   Westhovens, R ^a   Henry, N L ^c   Wildiers, H ^b   Paridaens, R ^b   Dieudonne A S ^a   Leunen, K ^a,b   Morales, L ^b   Verschueren, K ^a   Timmerman, D ^a   De Smet, L ^b   Vergote, I ^a   Christiaens, M R ^a,b   Neven, P ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Aromatase inhibitors; Breast cancer; Magnetic resonance imaging; Tamoxifen; Tenosynovial abnormalities

Indexed keywords

ANASTROZOLE; EXEMESTANE; LETROZOLE; TAMOXIFEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BIOACCUMULATION; BODY MASS; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTRACTURE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE SEVERITY; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRIP STRENGTH; HAND PAIN; HAND PARESTHESIA; HAND RADIOGRAPHY; HUMAN; MORNING STIFFNESS; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYNOVIAL FLUID; SYNOVITIS; TENDON DISEASE; TRIGGER FINGER; WRIST RADIOGRAPHY;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HAND STRENGTH; HUMANS; MIDDLE AGED; MUSCULOSKELETAL DISEASES; POSTMENOPAUSE; PROSPECTIVE STUDIES; SYNOVIAL MEMBRANE; TAMOXIFEN; TENDONS;

EID: 84873818997     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds290     Document Type: Article

References (26)

1. Coombes R, Hall E, Gibson L et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092.
2. Coates A, Keshaviah A, Thürlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrineresponsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25: 486-492.
3. Forbes JF, Cuzick J, Buzdar A et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9: 45-53.
4. Goss P, Ingle J, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802.
5. van de Velde CJ, Rea D, Seynaeve C et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 2011; 377: 321-331.
6. Cuzick J, Sestak I, Baum M et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010; 11: 1135-1141.
7. Joerger M, Thürlimann B. Update of the BIG 1-98 Trial: where do we stand? Breast 2009; 18(Suppl 3): S78-S82.
8. Partridge AH, LaFountain A, Mayer E et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008; 26: 556-562.
9. Dent S, De Valentin T, Vanermeer L. Long term toxicities in women with early stage breast cancer treated with aromatase inhibitors: data from a tertiary care center. Breast Cancer Res Treat 2006; 100: Abstract 4057.
10. Henry NL, Azzouz F, Desta Z et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 2012; 30: 936-942.
11. Morales L, Pans S, Verschueren K et al. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 2008; 26: 3147-3152.
12. Lintermans A, Van Calster B, Van Hoydonck M et al. Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis generating findings for its pathogenesis. Ann Oncol 2011; 22: 1763-1769.
13. Henry N, Jacobson J, Banerjee M et al. A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial highresolution wrist ultrasonography. Cancer 2010; 116: 4360-4367.
14. Dizdar O, Ozçakar L, Malas F et al. Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia. J Clin Oncol 2009; 27: 4955-4960.
15. Au B. Clinical features of joint symptoms observed in the Arimidex, Tamoxifen Alone or in Combination (ATAC) trial. Proc Am Soc Clin Oncol 2006; 24: 18S.
16. Kanematsu M, Morimoto M, Honda J et al. The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia. BMC Cancer 2011; 11: 436.
17. Sestak I, Cuzick J, Sapunar F et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 2008; 9: 866-872.
18. World Medical Association. Review of the declaration of Helsinki. JAMA 1997; 227: 925-926.
19. Henry N, Giles J, Ang D et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 2008; 111: 365-372.
20. Cvoro A, Tatomer D, Tee M et al. Selective estrogen receptor-beta agonists repress transcription of proinflammatory genes. J Immunol 2008; 180: 630-636.
21. Magliano M. Menopausal arthralgia: fact or fiction. Maturitas 2010; 67: 29-33.
22. Mao J, Stricker C, Bruner D et al. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 2009; 115: 3631-3639.
23. Ingle JN, Schaid DJ, Goss PE et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 2010; 28: 4674-4682.
24. Ingle J, Buzdar A, Schaid D et al. Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res 2010; 70: 3278-3286.
25. Rae JM, Sestak I, Henry NL et al. Correlation between gene variants in CYP19 (aromatase) and TCL1A with disease and tolerability endpoints in the ATAC trial. In SABCS. San Antonio, 2011.
26. Park IH, Lee YS, Lee KS et al. Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer. Cancer Chemother Pharmacol 2011; 68: 1263-1271.